Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael White

Showing results (91-100 of 585) with videos related to

Pageof 59
Sort By:
Journal of Clinical Pharmacology|August 16, 2021
Drugs of Abuse: How Clinical Pharmacology Brings Clarity to the ShadowsAnne N Nafziger, C Michael White
Open Access Journal of Clinical Trials|September 2, 2021
Taking Optogenetics into the Human Brain: Opportunities and Challenges in Clinical Trial DesignMichael White, Michael Mackay, Roger Whittaker
Journal of Clinical Pharmacology|June 13, 2020
Why Your Patients' Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVID-19 Is 100% DangerousC Michael White, Adrian V Hernandez
JAMA|June 28, 2021
Ranitidine and Risk of N-Nitrosodimethylamine (NDMA) FormationC Michael White, Adrian V Hernandez
Journal of Clinical Pharmacology|October 1, 2003
Levosimendan: implications for cliniciansBrian F McBride, C Michael White
Addiction (Abingdon, England)|January 24, 2018
Correction to: 'The effects of cannabis intoxication on motor vehicle collision revisited and revised' (2016)Ole Rogeberg, Rune Elvik, Michael White
Connecticut Medicine|February 10, 2007
A comparison of different protease inhibitors on coronary heart disease riskCraig I Coleman, C Michael White
Connecticut Medicine|May 10, 2007
Renin-angiotensin system inhibitors for prevention of new-onset atrial fibrillationWilliam L Baker, C Michael White
Current Medical Research and Opinion|May 18, 2026
Nitrous oxide abuse prevalence, mechanisms, treatments and preventionC Michael White, Lyla R White
Neuropharmacology|January 25, 2014
Designer psychostimulants: pharmacology and differencesLeslie Iversen, Michael White, Ric Treble
Pageof 59

Showing results (91-100 of 585) with videos related to

Sort By:
Pageof 59
Journal of Clinical Pharmacology|August 16, 2021
Drugs of Abuse: How Clinical Pharmacology Brings Clarity to the ShadowsAnne N Nafziger, C Michael White
Open Access Journal of Clinical Trials|September 2, 2021
Taking Optogenetics into the Human Brain: Opportunities and Challenges in Clinical Trial DesignMichael White, Michael Mackay, Roger Whittaker
Journal of Clinical Pharmacology|June 13, 2020
Why Your Patients' Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVID-19 Is 100% DangerousC Michael White, Adrian V Hernandez
JAMA|June 28, 2021
Ranitidine and Risk of N-Nitrosodimethylamine (NDMA) FormationC Michael White, Adrian V Hernandez
Journal of Clinical Pharmacology|October 1, 2003
Levosimendan: implications for cliniciansBrian F McBride, C Michael White
Addiction (Abingdon, England)|January 24, 2018
Correction to: 'The effects of cannabis intoxication on motor vehicle collision revisited and revised' (2016)Ole Rogeberg, Rune Elvik, Michael White
Connecticut Medicine|February 10, 2007
A comparison of different protease inhibitors on coronary heart disease riskCraig I Coleman, C Michael White
Connecticut Medicine|May 10, 2007
Renin-angiotensin system inhibitors for prevention of new-onset atrial fibrillationWilliam L Baker, C Michael White
Current Medical Research and Opinion|May 18, 2026
Nitrous oxide abuse prevalence, mechanisms, treatments and preventionC Michael White, Lyla R White
Neuropharmacology|January 25, 2014
Designer psychostimulants: pharmacology and differencesLeslie Iversen, Michael White, Ric Treble
Pageof 59